Emerging treatments for depression.

Emerging treatments for depression. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Emerging treatments for depression. Abstract Text:

Paul E Holtzheimer,Charles B Nemeroff,

Established treatments for depression are often effective. However, a significant number of patients show limited or no response. With advancements in the explanation of the underlying neurobiology of depression, several novel therapeutic approaches have been developed. Emerging drug targets include novel monoamine oxidase inhibitors, triple monoamine re-uptake inhibitors, omega-3 fatty acids, melatoninergic agonists and receptor antagonists for corticotropin-releasing factor(1), glucocorticoid, substance-P and NMDA. Developments in therapeutic focal brain stimulation include vagus nerve stimulation, transcranial magnetic stimulation, magnetic seizure therapy and deep brain stimulation. The role of psychotherapy, both as monotherapy and as adjunctive therapy, is an active avenue of investigation. Although data on these treatments are limited, preliminary results are encouraging. A major goal that remains to be achieved is the identification of predictors of response to the various antidepressant treatments that have diverse mechanisms of action.

Emerging treatments for depression. Publishing Authors By Initials

PE Holtzheimer,CB Nemeroff,

For similar behavioral disciplines and activities: psychotherapy research abstracts see: behavioral disciplines and activities: psychotherapy research

PUBMED ID PMID:

MEDLINE DATE:

Emerging treatments for depression. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert opinion on pharmacotherapy

VOLUME: 7

Page Numbers: 2323-39

Journal Abbreviation:

ISSN: 1744-7666

DAY: 3

MONTH: Dec

YEAR: 2006

Emerging treatments for depression. Information

Number of References: 200

LANGUAGE: eng

NlmUniqueID: 100897346

Emerging treatments for depression. Keywords Mesh Terms:

KEYWORDS: Psychotherapy

MESH TERMS: methods

Chemical & Substance for Abstract: Emerging treatments for depression. Information

Substance Name: Antidepressive Agents

Registry Number: 0

Grant and Affiliation Information for Emerging treatments for depression.

AFFILIATION: Emory University School of Medicine, Department of Psychiatry and Behavioural Sciences, 1841 Clifton Rd NE, 4th floor, Atlanta, Georgia 30329, USA. pholtzh@emory.edu

Country: England

AGENCY: United States NIMH

GRANT: MH 69056

ACRONYM: MH

MEDLINETA: Expert Opin Pharmacother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Emerging treatments for depression Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.